Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m sestamibi in bronchioloalveolar cell carcinoma.
Several studies have shown the benefit of fluorine-18 fluorodeoxy glucose (FDG) imaging in the differentiation of solitary pulmonary nodules. The majority of malignant tumor have a higher glucose metabolic rate as compared to benign lesions. However, there is a considerable variety in glucose metabolic rate that depends on the aggressiveness and histological subtype of the tumor. Technetium-99m sestamibi (MIBI) is another tumor imaging agent for SPECT. We present a case of bronchioloalveolar cell carcinoma with a false negative finding in FDG imaging and a positive finding in MIBI imaging. This case clearly indicates that the FDG uptake and MIBI uptake might provide different information regarding characteristics of lung cancer.
Department of Kanazawa PET Center, Kanazawa Cardiovascular Hospital, Japan. higuchi@med.kanazawa-u.ac.jp
Takahiro
T
Higuchi
Syoutoku
S
Tagawa
Naohiro
N
Yoshida
Tsutomu
T
Araki
Taketsugu
T
Tsuchiya
Koutarou
K
Higashi
Junichi
J
Taki
Seigo
S
Kinuya
Kenichi
K
Nakajima
Masatoshi
M
Ikeda
Masanobu
M
Namura
Norihisa
N
Tonami
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000000981:diagnostic imaging* / Q000473:pathology; D000368:Aged; D003937:Diagnosis, Differential; D005188:False Negative Reactions; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D008297:Male; D011859:Radiography; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012680:Sensitivity and Specificity; D017256:Technetium Tc 99m Sestamibi / Q000493:pharmacokinetics*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D017256:Technetium Tc 99m Sestamibi